Clinical trial · no report yet · Phase 3
NCT03040999
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
- NCT03040999 ↗
- Completed
- Merck Sharp & Dohme LLC
- 35 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 13 | |
| Podcasts | 13 | |
| X threads | 9 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Head and Neck Neoplasms
- Interventions
- Pembrolizumab; Placebo; Cisplatin; Accelerated Fractionation (AFX) Radiotherapy; Standard Fractionation (SFX) Radiotherapy
- Arms
- Pembrolizumab + Cisplatin + CRT · Experimental
- Placebo + Cisplatin + CRT · Placebo comparator
- Enrollment
- 804
- Primary outcomes
- Event-free Survival (EFS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Apr 5, 2017
- Primary completion
- May 31, 2022
- Results posted
- Yes
- Registry record
- NCT03040999 · updated Feb 4, 2026
Publications
linked from the registry- Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnal M, Delord JP, Mesia R, Taberna M, Waldron JN, Simon C, Gregoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. PubMed 38561010
- Machiels JP, Tao Y, Burtness B, Tahara M, Licitra L, Rischin D, Waldron J, Simon C, Gregoire V, Harrington K, Alves GV, Figueiredo Lima IP, Pointreau Y, M Hughes BG, Aksoy S, Hetnal M, Ge JY, Brown H, Cheng J, Bidadi B, Siu LL. Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. Future Oncol. 2020 Jun;16(18):1235-1243. doi: 10.2217/fon-2020-0184. Epub 2020 Jun 3. PubMed 32490686